Clinical Trials Browser

Phase 1 × Peritoneal Neoplasms × Breast × Clear all

Adenocarcinoma Of Esophagus, Breast Neoplasms, Diabetes Mellitus, Peritoneal Neoplasms

NCT05194072 2026-01-09

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

BreastGastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03304210 2023-11-07

PIPAC-nabpac

Phase 1 Completed

20 enrolled 16 charts

BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms

NCT03682744 2022-04-06

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

Phase 1 Withdrawn

BreastGastrointestinalGynecologic

Breast Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Phase 1 Completed

32 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01384253 2016-09-30

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Phase 1 Completed

18 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms

Clinical Trials

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

PIPAC-nabpac

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy